Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 118 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Erythema Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin

NCT03289832
View directory record Official record
Conditions
Healthy Adults
Interventions
Crucera-SGS, Meriva 500-SF
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 5, 2026, 11:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Phase 3 Interventional

An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations

NCT06538662
View directory record Official record
Conditions
Ocular Redness, Eye Irritation
Interventions
FID 123320 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
5 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Azusa, California • Newport Beach, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 5, 2026, 11:29 AM EDT
Completed No phase listed Observational Results available

Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale

NCT01636765
View directory record Official record
Conditions
Erythema, Rosacea
Interventions
No Intervention
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 5, 2026, 11:29 AM EDT
Completed No phase listed Observational

Urinary Continence Index for Prediction of Urinary Incontinence in Older Women

NCT01479816
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Not listed
Lead sponsor
Ananias Diokno
Other
Eligibility
55 Years and older · Female only
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Rochester, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

NCT04831047
View directory record Official record
Conditions
Ptosis, Eyelid, Conjunctiva Inflamed, Eye Manifestations
Interventions
Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 5, 2026, 11:29 AM EDT
Terminated Phase 2 Interventional Results available

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

NCT03363763
View directory record Official record
Conditions
Angiofibroma of Face, Tuberous Sclerosis
Interventions
Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment
Drug
Lead sponsor
Aucta Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01355458
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Clinton Township, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 5, 2026, 11:29 AM EDT
Completed No phase listed Observational

Sofia 2 Lyme FIA Whole Blood Clinical Study

NCT03238274
View directory record Official record
Conditions
Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans)
Interventions
Sofia 2 Lyme FIA testing
Device
Lead sponsor
Quidel Corporation
Industry
Eligibility
1 Year and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
11
States / cities
Fall River, Massachusetts • South Westport, Massachusetts • Duluth, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 5, 2026, 11:29 AM EDT
Not yet recruiting Phase 4 Interventional

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

NCT04007276
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions
brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution
Drug · Other
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects

NCT02737852
View directory record Official record
Conditions
Erythema, Edema
Interventions
Trojan "Chameleon" Personal Lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea

NCT01659853
View directory record Official record
Conditions
Erythema, Rosacea
Interventions
CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Evansville, Indiana • Louisville, Kentucky • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy

NCT03044197
View directory record Official record
Conditions
Prostate Cancer, Magnetic Resonance Imaging, Target Lesion, Fusion Biopsy, Clinically Significant Prostate Cancer, Transperineal
Interventions
MRI/ultrasound transperineal prostate biopsy, transrectal ultrasound-guided prostate biopsy
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

NCT04153188
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
The Vbeam® Prima System, Oxymetazoline HCL 1% Cream
Device · Drug
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

NCT05704114
View directory record Official record
Conditions
Acne Vulgaris, Post Inflammatory Hyperpigmentation, Post Inflammatory Pigmentation Change, Erythema, Skin Scarring
Interventions
Tazarotene 0.045% Lotion
Drug
Lead sponsor
Dr. Emmy Graber
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Not applicable Interventional

4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness

NCT03841032
View directory record Official record
Conditions
Rosacea
Interventions
Coppertone, BAY1183345
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Mango Intake of Skin Health in Postmenopausal Women

NCT03590756
View directory record Official record
Conditions
Wrinkle, Skin Red
Interventions
16 weeks mango intake
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 5, 2026, 11:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Phytonutrients on Vascular Health and Skin in Obese Males

NCT03496584
View directory record Official record
Conditions
Erythema, Inflammation
Interventions
Pomegranate Juice, Placebo Juice
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

NCT03954444
View directory record Official record
Conditions
Rosacea
Interventions
Oxymetazoline Hydrochloride, Rhofade Cream, 1%, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Not applicable Interventional Results available

Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte

NCT01491620
View directory record Official record
Conditions
Poikiloderma of Civatte, Dyschromia, Pigmentation Disorders, Telangiectasia, Photosensitivity Disorders
Interventions
532 nm KTP laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Phase 2 Interventional

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

NCT00249782
View directory record Official record
Conditions
Rosacea
Interventions
Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 5, 2026, 11:29 AM EDT
Completed No phase listed Observational

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

NCT05074719
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
10 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 5, 2026, 11:29 AM EDT
Withdrawn Phase 2 Interventional

Celecoxib in Preventing Skin Cancer

NCT00025051
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
celecoxib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, cancer prevention intervention, chemoprevention of cancer, growth factor antagonist therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 5, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

NCT02289352
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine, placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Hot Springs, Arkansas • Long Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 5, 2026, 11:29 AM EDT